Dr Paul Kelly is a Founding Partner of OneVentures and serves on the investment committee of OneVentures’ three main Funds, chairing the Fund III Investment Committee, and leads the healthcare and biotechnology practice across the firm. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of BiVACOR, and Clinical Genomics. He is also non-executive director of US based Agamatrix Inc.
Paul is an Australian physician and serial biotechnology entrepreneur with over 30 years’ experience in developing and commercialising biomedical innovations in the United States, Europe, United Kingdom and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, with a record of achievement in transforming ideas, technologies and products into sustainable successful businesses and delivering strong returns for shareholders and investors as a founder and CEO.
Paul joined the OneVentures team in 2009, as a co-founder of OneVentures’ first fund in 2010, after spending 15 years in the UK and USA (mostly in Boston, MA). Paul served as CEO of Gemini Genomics (Nasdaq:GMNI), one of the world’s first clinical genomics companies, which he co-founded in 1995 to discover and commercialise novel gene-based diagnostic and therapeutic targets. At Gemini, Paul as CEO led the company in one of the UK's largest biotechnology IPOs of the time, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world's leading research institutions and biotechnology and pharmaceutical companies. In 2001, Paul led the company's successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over US$250M. Paul then continued in the US working with local biotech and med-tech entrepreneurs and co-founded Agamatrix, now a leading bio-sensing medical device company with operations across the US and South East Asia, and Atomera (Nasdaq ATMR). He then served as President and CEO of Orchid Cellmark (Nasdaq:ORCH) at that time the world’s leading provider of genetic testing services in both the UK and US. During his tenure he developed and implemented major operational, financial and strategic restructuring growing revenues by over 50% in 2 years from US$40M to $60M per annum and increasing the companies valuation 10 fold.
While in the US Paul also served as President and CEO of Medcenter Solutions, a US based online medical education and pharmaceutical marketing company.
Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specialising in endocrinology at St Vincent's Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute of Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.
Paul has served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Paul is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Hons), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians. He also serves on the UNSW Medicine Dean's Advisory Group and serves on the Board of Directors of the Garvan Institute of Medical Research.
View in org chart
View in org chart